Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in
J M MacLennan1, F Shackley, P T Heath
1Department of Child Health, St George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, England. pheath@sghms.ac.uk
Insights
A new meningococcal C conjugate vaccine is safe and effective in infants. It stimulates a strong immune response and creates lasting immunologic memory against serogroup C meningococcal disease.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Immunology
Background:
- Neisseria meningitidis is a leading cause of infant meningitis and septicemia globally.
- The efficacy of meningococcal C conjugate vaccines in infants was previously unestablished.
Purpose of the Study:
- To assess the safety and immunogenicity of a novel meningococcal C conjugate vaccine in infants.
- To determine if the vaccine induces immunologic memory.
Main Methods:
- A double-blind, randomized controlled trial involving 182 healthy infants.
- Infants received either the meningococcal C conjugate vaccine or a hepatitis B control vaccine at 2, 3, and 4 months of age.
- Immunogenicity was measured by serum antibody levels and bactericidal activity at multiple time points, with a booster dose at 12 months.
Main Results:
- The meningococcal C conjugate vaccine was well-tolerated with no significant safety concerns.
- Infants receiving the conjugate vaccine demonstrated significantly higher antibody concentrations and serum bactericidal activity compared to controls after primary vaccination.
- These elevated antibody levels persisted at 12 months and showed a robust response after a booster dose.
Conclusions:
- The meningococcal C conjugate vaccine is safe and immunogenic in infants when administered with routine immunizations.
- The vaccine effectively induces immunologic memory, providing sustained protection against serogroup C Neisseria meningitidis.
Context:
Neisseria meningitidis is a common cause of meningitis and septicemia in infants worldwide. Whether a meningococcal C conjugate vaccine protects infants against the serogroup C strain is unknown.
Objectives:
To determine whether a meningococcal C conjugate vaccine is safe and immunogenic and induces immunologic memory in infants.
Design:
Single-center, double-blind, randomized controlled trial in 1995 and 1996.
Setting:
Community, Oxfordshire, England.
Participants:
One hundred eighty-two healthy infants.
Interventions:
Participants were randomly assigned to receive vaccination with 0. 5-mL doses of 1 of 2 lots of meningococcal C conjugate vaccine (groups 1 and 2; n=60 in each group) or a hepatitis B control vaccine (group 3; n=62), administered with routine immunizations at 2, 3, and 4 months of age. Approximately half of each group received meningococcal C conjugate vaccine and half received plain meningococcal polysaccharide vaccine (MPS) at 12 months of age.
Main Outcome Measures:
Serum antibodies to meningococcal C polysaccharide, assayed by enzyme-linked immunosorbent assay, and serum bactericidal activity (SBA), at 2, 3, 4, 5, 12, and 13 months of age; local and systemic reactions, recorded for 6 days after each vaccination, compared by intervention group.
Results:
Meningococcal C conjugate vaccine was well tolerated. After 3 doses, children in groups 1 and 2 achieved significantly higher meningococcal C IgG geometric mean concentrations (21 and 17 U/mL, respectively, vs 0.20 U/mL; P<.001) and SBA titers (629 and 420, respectively, vs 4.1; P<. 001) than controls. At 12 months, antibody concentrations had decreased in all groups but remained significantly higher in children vaccinated with meningococcal C conjugate vaccine (SBA, 24 and 16 in groups 1 and 2, respectively, vs 4.2 in group 3; P<.001). Following vaccination with MPS at 12 months of age, SBA in the meningococcal C conjugate vaccine group was significantly higher than in controls (SBA, 789 vs 4.5; P<.001).
Conclusions:
Our data indicate that meningococcal C conjugate vaccine is safe and immunogenic and results in immunologic memory when given with other routinely administered vaccines to infants at 2, 3, and 4 months of age. JAMA. 2000;283:2795-2801
Related Concept Videos
Survey Safety
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Vaccinations
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Trial and Error and Algorithm
Clinical Trials: Overview

